Evidence map›Paper›PMID 36103987›Full record

GuidelineTransplantation and cellular therapy2022

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).

Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, Alpana Waghmare, Maheen Z Abidi, Steven Pergam, Michael Boeckh, Sanjeet Dadwal, Mini Kamboj, Susan Seo and 2 more

Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06879340 (A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06879340 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2040Enrolled54ConditionsB-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic LeukemiaArmsDuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy)
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  10. Review
  11. Review
  12. COVID-19 surveillance in a bone marrow transplantation unit: experience from a Brazilian tertiary-care teaching hospital.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Old Pathogens-New Patient Types: Infections in a CAR T-Cell Recipient. Could It Get Any More Complicated?Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Veronica DiovertiAssistant Professor of Medicine, Johns Hopkins University, Baltimore, Maryland. Electronic address: mdiover1@jhmi.edu.
Zeinab El BoghdadlyAssistant Professor of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Zainab ShahidAttending physician, Memorial Sloan Kettering Cancer Center, New York, New York.
Alpana WaghmareAssociate Professor of Pediatrics, University of Washington, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington.
Maheen Z AbidiAssistant Professor of Medicine, University of Colorado, Denver, Colorado.
Steven PergamProfessor, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington, Seattle, Washington.
Michael BoeckhFred Hutchinson Cancer Center, Seattle, Washington; Professor of Medicine, University of Washington, Seattle, Washington.
Sanjeet DadwalProfessor of Medicine, City of Hope, Duarte, California.
Mini KambojAssociate Professor of Medicine, Weill Cornell Medical College, New York, New York; Memorial Sloan Kettering Cancer Center, New York, New York.
Susan SeoMemorial Sloan Kettering Cancer Center, New York, New York; Professor of Clinical Medicine, Weill Cornell Medical College, New York, New York.
Roy F ChemalyProfessor of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Genovefa A PapanicolaouMemorial Sloan Kettering Cancer Center, New York, New York; Professor of Medicine, Weill Cornell Medical College, New York, New York.

Funding

CMV and CMV-Immune Responses in Geriatric Conditions Post-Kidney Transplant (CMV-GeriKT)K23AG073534 · NIA · UNIVERSITY OF COLORADO DENVER · PI ABIDI, MAHEEN ZEHRA · 2021 to 2025
$944k
NIA NIH HHS K23 AG073534
6 · The paper itself

Abstract

This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

Indexed as

COVID-19Hematopoietic Stem Cell TransplantationAdultCell- and Tissue-Based TherapyChildHumansSARS-CoV-2Cellular therapyCOVID-19Hematopoietic cell transplantationSARS-CoV-2

Identifiers

PMID36103987
PMCPMC9464362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.